Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223296 | 0.77 | — | — | |
| SCHEMBL2751393 | 0.74 | NOTUM (0.42) | — | |
| SCHEMBL7223525 | 0.73 | ELANE (0.39) | — | |
| SCHEMBL2028222 | 0.73 | GRM5 (0.51) | UHRF1RXRAGRIN1GRIN2BGRM5 | |
| SCHEMBL1492667 | 0.73 | ADRB1 (0.43) | RXRAGRIN1GRIN2B | |
| SCHEMBL13097439 | 0.71 | CYP2A6 (0.47) | UHRF1RXRAGRIN1GRIN2BDYRK1A | |
| SCHEMBL22725120 | 0.71 | RXRA (0.48) | UHRF1RXRAGRIN1GRIN2BCCR1 | |
| SCHEMBL2752248 | 0.71 | NOTUM (0.44) | RXRAGRIN1GRIN2B | |
| SCHEMBL671068 | 0.71 | NOTUM (0.44) | — | |
| SCHEMBL29984511 | 0.71 | UHRF1 (0.48) | UHRF1RXRAGRIN1GRIN2BGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-01-20 | — | — | US | disclosed |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3856348-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | Incyte Corporation (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068729-A1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS | INCYTE CORPORATION (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095250-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | UHRF1 4493/4885RXRA 655/4885GRIN1 3216/4885 |
| US-20220017521-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | ALK, FGFR1, FGFR2 | UHRF1 4493/4885RXRA 655/4885GRIN1 3216/4885 |
| US-11111247-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | UHRF1 4493/4885RXRA 655/4885GRIN1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.